BioCentury
ARTICLE | Distillery Therapeutics

Cancer

July 10, 2017 6:04 PM UTC

Mouse studies identified a chimeric IL-2-Fc fusion protein that could help treat cancer. The fusion protein consisted of a human IL-2 variant containing three point mutations, linked to the Fc domain of mouse IgG2c. In mice, the fusion protein increased expansion of NK cells and CD8+ cells and decreased expansion of Tregs compared with a wild-type IL-2/IL-2 mAb complex, and had a longer serum half-life and lower pulmonary and hepatic toxicity than the IL-2/mAb complex or a chimeric fusion of wild-type IL-2 and the mouse Fc domain. In mouse models of melanoma or colorectal cancer, the variant IL-2/mouse Fc domain fusion protein decreased tumor growth compared with vehicle. Next steps could include testing the fusion protein in additional models of cancer...

BCIQ Target Profiles

Interleukin-2 (IL-2)